ATAI Life Sciences NV (9VC) — Financial Flexibility Index
ATAI Life Sciences NV (9VC) has a Financial Flexibility Index of -0.22x as of September 2025. Free cash flow of €-17.90 Million (operating CF €-23.26 Million minus capex €5.36 Million) represents 0% of total liabilities (€79.91 Million). Check 9VC intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
ATAI Life Sciences NV Financial Flexibility Index (2019–2024)
Historical Financial Flexibility Index trend for ATAI Life Sciences NV across 6 annual periods. For the full cash flow conversion analysis, see ATAI Life Sciences NV (9VC) cash conversion ratio.
Annual Financial Flexibility Index for ATAI Life Sciences NV (2019–2024)
Year-by-year free cash flow to debt coverage for ATAI Life Sciences NV. Explore 9VC debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.92x | €-82.34 Million | €-82.44 Million | €42.83 Million | ▼ -13.1% |
| 2023 | -1.70x | €-83.53 Million | €-84.12 Million | €49.16 Million | ▲ +34.8% |
| 2022 | -2.61x | €-103.44 Million | €-104.47 Million | €39.67 Million | ▼ -18.4% |
| 2021 | -2.20x | €-62.12 Million | €-63.25 Million | €28.21 Million | ▼ -72.1% |
| 2020 | -1.28x | €-20.71 Million | €-20.77 Million | €16.18 Million | ▲ +59.5% |
| 2019 | -3.16x | €-7.83 Million | €-7.85 Million | €2.48 Million | — |